CTOs on the Move

Atomwise

www.atomwise.com

 
Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.atomwise.com
  • 717 Market Street Suite 800
    San Francisco, CA USA 94103
  • Phone: 650.720.8923

Executives

Name Title Contact Details

Funding

Atomwise raised $45M on 03/07/2018
Atomwise raised $123M on 08/11/2020

Similar Companies

Matthew Gibbs

CipherBio@SVB: Search life science fundraising news and data to discover innovative companies backed by venture investors https://t.co/mmTCuwa0Mc

Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry seven years in a row by the Dow Jones Sustainability Indices. The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

Agena Bioscience

Agena Bioscience’s scalable MassARRAY System enables one day assay turnaround times on a wide variety of targeted genetic tests.

Bellus Health

BELLUS Health is a clinical stage biotechnology company developing novel therapeutics for the treatment of chronic cough and other chronic disorders triggered by hypersensitization.

ReCode Therapeutics

ReCode Therapeutics is a biopharmaceutical company developing precision medicines for pulmonary diseases with significant unmet medical need.